Search clinical trials for: CycloSPORINE Ophthalmic Suspension

Total 3531 results

Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Allergan

Completed

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

Dry Eye Syndromes

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Bausch & Lomb Incorporated

Completed

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Dry Eye Syndrome

United States
University of North Carolina, Chapel Hill
Allergan

Completed

Topical Cyclosporine Suspension for the Treatment of Brittle Nails

Brittle Nail Syndrome

United States
Mahidol University

Completed

Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye

Stevens-Johnson Syndrome

Thailand
Santen Inc.
ActualEyes Inc.

Active, not recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States, France, India
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
M.D. Anderson Cancer Center
Allergan

Withdrawn

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Epiphora
The Cleveland Clinic

Completed

Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia

Aplastic Anemia

United States
Center for Ophthalmic and Vision Research, LLC
Sun Pharmaceutical Industries Limited

Completed

CEQUA for Sjogren's Syndrome Dry Eye

Dry Eye | Dry Eye Syndromes | Sjogren's Syndrome

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)

Kerato Conjunctivitis Sicca

United States
Rennes University Hospital
Novartis

Terminated

Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation

Chronic Hepatitis C | Evidence of Liver Transplantation

France
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT

Ocular Graft-versus-host Disease

Mexico
Johns Hopkins University

Completed

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Atopic Keratoconjunctivitis

United States
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Solid Neoplasm

United States, Canada
Chengdu University of Traditional Chinese Medicine

Completed

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye (AST/SS)

Dry Eye | Sjogren's Syndrome | Ocular Surface Disease

China
Sun Pharmaceutical Industries Limited

Completed

Effect of Cequa™ in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Boston Sight
Allergan

Completed

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

Ocular Surface Disease

United States
Campus Bio-Medico University

Completed

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (CSA2020)

Ocular Inflammation | Ocular Surface Disease

Italy
Aurinia Pharmaceuticals Inc.

Completed

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Dry Eye

United States
University of Waterloo
Sun Pharmaceutical Industries Limited

Recruiting

Improving Drop Instillation Comfort of a Cyclosporine A Solution

Dry Eye Disease

Canada
Taejoon Pharmaceutical Co., Ltd.

Recruiting

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Dry Eye Syndrome

Korea, Republic of
Alcon Research

Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma
Seoul National University Hospital

Completed

Comparison Study of Psoriasis Severity Assessment Tools

Psoriasis

Korea, Republic of
Hanlim Pharm. Co., Ltd.

Completed

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group (Cyclosporine)

Dry Eye Syndromes

Korea, Republic of
University of Alabama at Birmingham

Completed

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers

Contact Lens Wearers With Dry Eye Syndrome

United States
Hanlim Pharm. Co., Ltd.

Completed

Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease (HL_TSPR_302)

Dry Eye Syndromes

Korea, Republic of
Chulalongkorn University
Allergan

Unknown

Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

Dry Eye

Thailand
Taejoon Pharmaceutical Co., Ltd.

Completed

Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients

Dry Eye | Dry Eye Syndromes

Korea, Republic of
Singapore Eye Research Institute

Unknown

Ikervis for DED Due to GVHD Post Allo-HSCT (Ikervis)

Leukemia (Both ALL and AML) | MDS-EB-1

Singapore
Allergan

Completed

Study of Cyclosporine in Post-LASIK Patients

Laser In Situ Keratomileusis

United States
Baylor College of Medicine
Allergan

Terminated

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface (CsA)

Dry Eye

United States
Novaliq GmbH

Recruiting

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

Dry Eye Disease

United States
Instituto de Investigación Hospital Universitario...

Recruiting

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response (DermAtOmics)

Atopic Dermatitis

Spain
Guangzhou HuiBoRui Biological Pharmaceutical Technology...
Parexel

Unknown

Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment

Corneal Neovascularization

United States
Boston Sight

Withdrawn

Novel Use of Restasis and PROSE Devices

Ocular Surface Disease

United States
Stanford University

Completed

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Lymphoma, Non-Hodgkin | Mycoses | Lymphoma, T-Cell, Cutaneous | Sezary Syndrome | Cutaneous T-cell Lymphoma | Bone Marrow Transplant Failure

United States
Allergan

Completed

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Dry Eye Disease

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Allergan

Completed

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (STRIDE 2)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Padagis LLC

Completed

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Glaucoma, Open-Angle

United States
Allergan

Completed

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® (EMPOWER)

Dry Eye Syndromes

United States
Mahidol University

Completed

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

Thailand
SCAI Therapeutics

Completed

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Dry Eye Syndromes

Korea, Republic of

3

Subscribe